中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [459]
西北高原生物研究所 [46]
合肥物质科学研究院 [35]
昆明植物研究所 [29]
大连化学物理研究所 [23]
上海生物化学与细胞... [23]
更多
采集方式
OAI收割 [738]
iSwitch采集 [20]
内容类型
期刊论文 [736]
学位论文 [14]
会议论文 [8]
发表日期
2024 [7]
2023 [27]
2022 [39]
2021 [50]
2020 [32]
2019 [58]
更多
学科主题
Pharmacol... [12]
物理化学 [8]
生命有机化学 [8]
Cell Biolo... [7]
Neuroscien... [7]
Oncology [6]
更多
筛选
浏览/检索结果:
共758条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
发表日期升序
发表日期降序
题名升序
题名降序
作者升序
作者降序
The compound BTB06584 is an IF1-dependent selective inhibitor of the mitochondrial F1Fo-ATPase1
期刊论文
OAI收割
出版物, 3111, 期号: 0, 页码: 1-38
作者:
Fabrice Ivanes
;
Danilo Faccenda
;
Jemma Gatliff
;
Ahmed A Ahmed
;
Stefania Cocco
  |  
收藏
  |  
浏览/下载:176/0
  |  
提交时间:2017/07/24
Mitochondrial F1fo Atp Synthase
If1
Ischemia-induced Death
Btb06584
Pinotage
Targeting JMJD1C to selectively disrupt tumor T
reg
cell fitness enhances antitumor immunity
期刊论文
OAI收割
NATURE IMMUNOLOGY, 2024, 页码: 32
作者:
Long, Xuehui
;
Zhang, Sulin
;
Wang, Yuliang
;
Chen, Jingjing
;
Lu, Yanlai
  |  
收藏
  |  
浏览/下载:17/0
  |  
提交时间:2024/03/25
Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
d
]pyrimidin-7(6
H
)-one" Scaffold for the Treatment of B Cell Lymphoma
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 67, 期号: 4, 页码: 2884-2906
作者:
Liang, Xuewu
;
Yu, Haolan
;
Liang, Renwen
;
Feng, Zhuanghui
;
Saidahmatov, Abdusaid
  |  
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2024/04/09
JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers
期刊论文
OAI收割
CANCER LETTERS, 2024, 卷号: 582, 页码: 15
作者:
Lu, Xuxiu
;
Yu, Rilei
;
Li, Zhen
;
Yang, Mengke
;
Dai, Jiajia
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2024/04/07
Acquired resistance
Cancer
NSCLC
JC-010a
SHP2
Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor
期刊论文
OAI收割
BIOORGANIC CHEMISTRY, 2024, 卷号: 143, 页码: 16
作者:
Sun, Yaoliang
;
Chen, Zhiwen
;
Liu, Guobin
;
Chen, Xiaoai
;
Shi, Zihan
  |  
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2024/03/25
Inhibitor
Cancer
Threonine tyrosine kinase (TTK)
Covalent
Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 264, 页码: 10
作者:
Chen, Guofeng
;
Xie, Hang
;
Liu, Jiayuan
;
Shao, Qiang
;
Li, Minjun
  |  
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2024/01/26
Methyl substitution
Selectivity
FABP4 inhibitor
Anti-inflammation
Metabolic stability
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
G12D
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 67, 期号: 2, 页码: 1147-1167
作者:
Zhou, Chuan
;
Fan, Zisheng
;
Gu, Yuejiao
;
Ge, Zhiming
;
Tao, Zhaofan
  |  
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2024/02/27
Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 卷号: 263, 页码: 21
作者:
Zhang, Hongjin
;
Lin, Guohao
;
Jia, Suyun
;
Zhang, Ying
;
Wu, Jianbo
  |  
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2024/01/26
Thieno[3
d ]pyrimidine derivative
Cyclin-dependent kinase 7
Small molecule inhibitor
Kinome selectivity
Triple negative breast cancer
A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
期刊论文
OAI收割
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 卷号: 191, 页码: 9
作者:
Yang, Xin-Mei
;
Yang, Yang
;
Yao, Bu-Fan
;
Ye, Pan-Pan
;
Xu, Yan
  |  
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2023/12/11
COVID-19
Simnotrelvir
Safety
Pharmacokinetics
Healthy subjects
Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma
期刊论文
OAI收割
ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4748-4764
作者:
  |  
收藏
  |  
浏览/下载:9/0
  |  
提交时间:2024/01/26
Small molecule inhibitor
Tumor microenvironment
Immune-checkpoint
immune-deficient mouse models
including temozolomide (TMZ) insensitive tumors. Notably